{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:54:21Z","timestamp":1791863661818,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010304","name":"Civilingeni\u00f8r Walter Christensen og hustru O. Kristiane Christensens Fond","doi-asserted-by":"publisher","award":["850-22-55166-17-LNG"],"award-info":[{"award-number":["850-22-55166-17-LNG"]}],"id":[{"id":"10.13039\/501100010304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","award":["ID 6110-00518B"],"award-info":[{"award-number":["ID 6110-00518B"]}],"id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","award":["ID 4108-00004B"],"award-info":[{"award-number":["ID 4108-00004B"]}],"id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013325","name":"Swiss Re Foundation","doi-asserted-by":"publisher","award":["P500PM_210867"],"award-info":[{"award-number":["P500PM_210867"]}],"id":[{"id":"10.13039\/100013325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004787","name":"The Research Council","doi-asserted-by":"publisher","award":["R130-A5324"],"award-info":[{"award-number":["R130-A5324"]}],"id":[{"id":"10.13039\/501100004787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.euroneuro.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T19:03:30Z","timestamp":1723230210000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research"],"prefix":"10.1016","volume":"88","author":[{"given":"Friederike","family":"Holze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-1844","authenticated-orcid":false,"given":"Martin K.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Svarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nic","family":"Gillings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea S.","family":"Stenbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-9732","authenticated-orcid":false,"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-0611","authenticated-orcid":false,"given":"Patrick M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-6866","authenticated-orcid":false,"given":"Gitte M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2024.07.003_bib0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","article-title":"Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants","volume":"26","author":"Becker","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0002","first-page":"120","article-title":"A high-resolution in vivo atlas of the human brain's serotonin system","volume":"37","author":"Beliveau","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biopsych.2022.10.012","article-title":"Brain serotonin release is reduced in patients with depression: a [(11)C]cimbi-36 positron emission tomography study with a D-amphetamine challenge","volume":"93","author":"Erritzoe","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","article-title":"Serotonin 2A receptor agonist binding in the human brain with [(1)(1)C]Cimbi-36","volume":"34","author":"Ettrup","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroimage.2016.02.001","article-title":"Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin","volume":"130","author":"Ettrup","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0006","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00501438","article-title":"Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calf","volume":"326","author":"Frenken","year":"1984","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neuroimage.2013.12.021","article-title":"Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data","volume":"92","author":"Greve","year":"2014","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0893-133X(97)00044-4","article-title":"Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography","volume":"17","author":"Grunder","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2016.09.001","article-title":"Imaging in central nervous system drug discovery","volume":"47","author":"Gunn","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0011","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0012","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J. Cereb Blood Flow Metab."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0014","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0016","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1023\/A:1027366413289","article-title":"[3H]ketanserin binding in human brain postmortem","volume":"22","author":"Marazziti","year":"1997","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0017","first-page":"794","article-title":"Plasma protein binding of ketanserin and its distribution in blood","volume":"38","author":"Meuldermans","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16368","article-title":"Ligand bias and inverse agonism on 5-HT(2A) receptor-mediated modulation of G protein activity in post-mortem human brain","author":"Muneta-Arrate","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0019","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"Nordstrom","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-199120040-00002","article-title":"Clinical pharmacokinetics of ketanserin","volume":"20","author":"Persson","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00544018","article-title":"Pharmacokinetics of ketanserin in man","volume":"25","author":"Reimann","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2024.07.003_bib0023","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0024","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1002\/hbm.25138","article-title":"Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels","volume":"41","author":"Spies","year":"2020","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neuroimage.2004.10.017","article-title":"MR-based automatic delineation of volumes of interest in human brain PET images using probability maps","volume":"24","author":"Svarer","year":"2005","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2024.07.003_bib0026","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24001597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24001597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T14:38:46Z","timestamp":1729262326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24001597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"alternative-id":["S0924977X24001597"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.07.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}